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Abstract: 
Opioid use in pregnancy has increased dramatically over the past decade. Since prenatal 
opioid use is associated with numerous obstetrical and neonatal complications, this now has 
become a major public health problem. In particular, in utero opioid exposure can result in neonatal 
abstinence syndrome (NAS) which is a serious condition characterized by central nervous system 
hyperirritability and autonomic nervous system dysfunction. The present review seeks to define 
current practices regarding the approach to the pregnant mother and neonate with prenatal opiate 
exposure. Although the cornerstone of prenatal management of opioid dependence is opioid 
maintenance therapy, the ideal agent has yet to be definitively established. Pharmacologic 
management of NAS is also highly variable and may include an opioid, barbiturate, and/or α-
agonist. Genetic factors appear to be associated with the incidence and severity of NAS. 
Establishing pharmacogenetic risk factors for the development of NAS has the potential for 
creating opportunities for “personalized genomic medicine” and novel, individualized therapeutic 
interventions.   
Prevalence of opiate use in pregnancy 
Opiate use in the US has risen dramatically in recent years. In 2012, health care 
professionals dispensed an average of  82.5 opioid prescriptions per 100 persons, with significant 
variation observed between states (up to 143 prescriptions per 100 persons in some southern 
states).1 Women of reproductive age have been particularly impacted, with approximately 28% of 
privately-insured and 39% of Medicaid enrolled women age 15-44 years filling a prescription for 
an opioid medication each year for five consecutive years.2 Illicit use of opioids (especially heroin) 
has also increased significantly over this same time period. Consistent with these national trends, 
maternal opiate use in pregnancy has also increased from 1.19 per 1000 births in 2000 to 5.63 in 
3 
 
2009, with 60% of these mothers insured through Medicaid.3 In parallel, the burden of NAS has 
increased from 7 to 27 per 1000 NICU admissions between 2004 and 2013.4 Factors associated 
with worse NAS outcomes include maternal use of cigarettes and other psychotropic medications 
such as benzodiazepines and selective serotonin re-uptake inhibitors (SSRIs).5-8 The impact of 
these drug-drug interactions on the fetus and how they might influence NAS have not been fully 
characterized. 
Maternal agonist treatment for opiate-dependent pregnant women 
Substance abuse use during pregnancy is associated with fetal death, intrauterine growth 
retardation, placental insufficiency, postpartum hemorrhage, pre-eclampsia, and premature rupture 
of membranes.9 Maternal opioid-substitution programs have been shown to improve pregnancy 
outcomes by minimizing the use of illicit drugs, reducing withdrawal and high risk behaviors, and 
improving compliance with prenatal care.10 The most common FDA approved agents are 
methadone and buprenorphine. The pharmacokinetics of methadone in pregnant women differ 
from the non-pregnant population and change significantly throughout pregnancy. For example, 
the half-life of methadone falls from an average of 23 hours in non-pregnant women to 
approximately 8 hours in pregnant women.11 The reduced half-life and increased volume of 
distribution in the pregnant woman often necessitates increased dosing as pregnancy progresses. 
Established drug-drug interactions exist between methadone and some anti-epileptics, rifampin, 
and several anti-retrovirals often used in the treatment of human immunodeficiency virus infection. 
An alternative to methadone for maintenance therapy in pregnancy is buprenorphine, a 
partial mu-opioid agonist.12 Demonstrated advantages of buprenorphine over methadone include 
a diminished risk of overdose (due to low intrinsic receptor efficacy), less abrupt withdrawal, fewer 
drug-drug interactions, and prescriptions that are easier to obtain.13,14 In addition, buprenorphine 
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has been associated with an overall reduction in the incidence and severity of NAS compared to 
methadone.15,16 Disadvantages of buprenorphine include increased dropout rates, more difficult 
initiation of treatment, potential risk of drug diversion, less social support and counseling 
compared to conventional methadone maintenance programs, and lack of long-term pregnancy and 
childhood safety data.17, 18 
Neonatal Abstinence Syndrome 
While opioid maintenance treatment during pregnancy improves maternal and infant 
outcomes, it does not prevent the development of NAS. In utero exposure to opioids in pregnancy 
is associated with a 60-80% risk of NAS requiring pharmacologic treatment.4 NAS is a highly 
variable condition characterized by central nervous system hyperirritability, autonomic nervous 
system dysfunction and gastrointestinal disturbances. Defining features include: excessive crying, 
irritability, poor sleep, increased muscle tone, tremors, excoriations of the skin from excessive 
movements, hyperthermia, loose stools, yawning, sweating, nasal stuffiness, and sneezing. In 
addition, seizures can occur in 2-11% of infants with NAS.19,20 The specific pathophysiology of 
neonatal opioid withdrawal and the factors that influence severity remain incompletely understood. 
However, altered levels of neurotransmitters such as norepinephrine, dopamine, and serotonin are 
believed to play a significant role.19, 21-23 Conceptually, every infant with in utero opioid exposure 
resides along the continuum of signs of withdrawal. While some have mild, clinically insignificant 
signs, others have more severe disease that significantly impacts growth and development without 
treatment. Thus, the diagnosis of NAS is not made by the need for pharmacologic treatment, but 
instead by the cardinal signs of neonatal withdrawal. 
The most common approach to monitoring infants for NAS is the Finnegan scoring 
instrument. The scoring is performed in a serial manner to help determine: 1) which neonates 
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require pharmacologic therapy; 2) how dosing should be escalated; and 3) when weaning should 
occur. The traditional Finnegan scoring system consists of a 31-item scale used to assess the 
presence and severity of various NAS-associated symptoms and is performed every 3-4 hours.19 
Each evaluation should take into account behavior observed over the entire 3-4 hour period leading 
up to the assessment. A score of 7 on day 2 of life corresponds with the 95th percentile for non-
exposed infants. A score of >8 is highly suggestive of NAS even in those denying opioid use 
during pregnancy.24 The Finnegan scoring system is primarily designed for term infants, making 
use in both preterm and older (>30 day) infants non-standardized. A significant limitation of the 
scoring system is the significant intra-observer variability that has been documented.16 Thus, 
continuous staff education and gold standard evaluations are a critical piece of optimal NAS care. 
Maternal history taken in a neutral and non-judgmental fashion will identify the large 
majority of infants with in utero exposure. An adjunct to verbal history is typically provided via 
urine or meconium screening of the newborn. Hair and umbilical cord analyses have also been 
proposed, but their utility in medical management is limited.25 Urine screening has the advantage 
of being easily performed, but is limited by the identification of only recent exposures. Meconium 
testing has the advantage of screening for substance exposure extending back as far as 20 weeks 
gestation. 
Treatment 
The primary clinical concern for withdrawal is the impact upon growth and development. 
Secondary effects include impaired maternal bonding, infant discomfort, and seizures. The most 
effective treatment approaches are those that employ a systematic, multidisciplinary, and 
multimodal approach.  Given the complexity of the disease and setting of treatment, a continuous 
process of quality improvement will lead to improved patient outcomes. Treatment is optimized 
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when staff engage mothers with respect and acknowledge the struggles with substance abuse. Such 
mothers, who often experience other psychiatric and psychosocial comorbidities, are often 
sensitive to the perceived judgment of staff. 
Non-Pharmacologic Treatment 
All infants at risk for NAS should be managed with a non-pharmacologic approach that 
involves creating a quiet and soothing environment with the avoidance of excessive environmental 
stimulation. Frequent hypercaloric feeds minimize hunger and promote growth. Rooming-in may 
reduce the need for pharmacologic treatment and should be strongly encouraged if the situation 
permits. Maternal involvement in the infant’s care is an important component of non-
pharmacologic management.19,26 
In the absence of maternal HIV infection, illicit drug use, or other contraindications, both 
the American Congress of Obstetrics and Gynecology (ACOG) and the American Academy of 
Pediatrics (AAP) encourage breastfeeding in women in methadone or buprenorphine treatment 
programs.18,27 Breastfeeding has been associated with a decrease in the incidence and severity of 
NAS and should be encouraged.28 The amount of maternally transferred methadone or 
buprenorphine is low, but an additional therapeutic benefit is the physical contact and bonding. 
Multimodal institutional policies that promote safe breastfeeding are effective in increasing the 
very low rates of breast feeding among infants at risk for NAS. 29   
Pharmacologic Therapy 
Pharmacologic treatment is required in the 60-80% of infants who do not respond to non-
pharmacologic therapy.20 Primary outcome measures in comparing treatments are duration of 
treatment, length of hospital stay, and need for adjunctive therapies. Despite a significant effort 
within the medical community to find the ideal drug and dosing regimen, the most important 
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predictor of success in reducing total length of hospital stay and duration of pharmacologic 
treatment is the use of a standardized institutional protocol based on best practice (promoted by 
the Vermont-Oxford Neonatal Network). The use of a standardized approach is more important 
than the use of a specific drug (methadone or morphine) for pharmacologic treatment of NAS.  In 
Central Ohio, a 50% decrease in length of stay (36 to 18 day) was achieved through the use of a 
Model for Improvement approach that involved standardized assessment and treatment protocols, 
educational outreach and assessment, and involvement of multiple stakeholders.30 Protocols 
developed in a multidisciplinary fashion have the highest potential for success 
[www.mededportal.org/icollaborative/resource/3920].    
The AAP, multiple Cochrane reviews, and expert reviews identify opioid replacement as 
first line pharmacotherapy treatment for NAS.20,27,31-33 However, several treatment approaches are 
used and no universal standard of care for NAS exists. The most commonly used treatment 
approach initially uses an opioid. If there is inadequate response to a single agent at higher doses, 
a second line agent of phenobarbital or clonidine is used as an adjunct. However, there is 
significant heterogeneity in treatment approaches and the optimal treatment protocol has not been 
established in large, well-controlled studies.4,34-36 Variations include the initial use of 
phenobarbital monotherapy instead of an opioid, or initial dual therapy with an opioid and either 
phenobarbital or clonidine. In all cases, the approach involves rapid up-titration in dose to control 
symptoms, followed by a gradual weaning of typically 10% per day if signs of withdrawal allow. 
Opioids 
Morphine and Methadone 
The two opioids used in practice are oral morphine and methadone. Morphine is the 
primary opioid used in the majority of centers, with methadone being used in 10-20% of 
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hospitals.34  The pharmacokinetics of morphine in neonates are well established.37 Due to a short 
half-life, morphine is administered every 3-4 hours. The two approaches to dosing morphine are a 
fixed mg/kg dose or a fixed mg (non-weight based) dose depending upon severity of withdrawal 
signs/symptoms (Figure 1). These two approaches have not been directly compared in a clinical 
trial, with dosing protocols provided in Table 1. Comparisons between institutions using one or 
the other approach are not valid due to significant differences in patient population, robustness of 
institutional protocols, prenatal care, and other non-pharmacologic factors.  
An alternative to morphine is methadone, which has a longer half-life, requiring less 
frequent administration and titration. The inter-individual pharmacokinetic variability in adults 
and children is high.38-40 A recently completed but unpublished clinical trial investigating oral 
methadone pharmacokinetics (NCT01754324) confirmed significant variability in response in 
NAS patients (Personal communication J Wiles). There are significant variations in dosing 
regimens used. Typically doses begin around 0.2 mg/kg/day in 2-6 divided doses a day. Some 
regimens employ a loading dose of 0.1 mg/kg.41 Modeling and simulation techniques to rationally 
craft a dosing regimen based upon emerging pharmacokinetic data are being pursued. Most 
formulations of methadone contain ethanol, though a stable ethanol-free methadone solution can 
be formulated using pure methadone powder. While the pharmacokinetic variability of methadone 
is of some concern in the outpatient setting, use has generally been safe. Similarly, no QT 
prolongation in methadone treated neonates has been noted nor has there has been documented 
morbidity in infants treated for NAS.40  
There is no consensus as to the superiority of morphine or methadone. A retrospective 
review of administrative data from 14 children’s hospitals revealed a length of treatment 45% 
lower for methadone than morphine.34 This is in contrast to retrospective review of central Ohio 
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patients in which outcomes were equal for both treatments.30 A 2015 single site clinical trial in 78 
infants demonstrated a 14 day length of treatment with methadone compared to 21 days for 
morphine.42 A more definitive answer will be generated by the multi-center BABY trial currently 
underway (NCT01958476). 
Buprenorphine 
NAS treatment with sublingual buprenorphine has been investigated.31,43 While a phase 1 
investigation suggested a 30% reduction in length of stay compared to morphine, a definitive 
randomized clinical trial will be completed in 2016 (NCT01452789). Like phenobarbital and most 
methadone formulations, buprenorphine contains a significant amount of ethanol. Despite 
widespread use in many medications as a preservative (e.g. extrinsic), the pharmacodynamic and 
safety profile of ethanol in neonates has not well defined.44 A pharmacokinetic model of 
buprenorphine in infants with NAS has been generated.45 This can serve as the basis of modeling 
and simulation to optimize dose and dose schedules that takes into account developmental 
ontogeny of metabolic processes and the natural history of symptom resolution in NAS.  
Phenobarbital 
Phenobarbital (phenobarbitone in the United Kingdom) is a barbiturate antiepileptic. 
Although it is often used as an adjunctive treatment once a maximum opioid dose is reached, it 
can be given as an initial adjunct in combination therapy with an opioid or as initial 
monotherapy.46-48 The half-life of phenobarbital in neonates is 115 hours at 1 week and declines 
to 67 hours after 4 weeks.49 This prolonged half-life means many standard doses (usually 5 mg/kg) 
are needed to reach steady state, and explains the improved outcome with a loading dose.50 The 
typical loading dose is 20 mg/kg, which leads to therapeutic concentrations for the majority of 
infants. It should be noted that the therapeutic range has been defined for treatment of seizures, 
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but it does provide useful information about safety and appropriate dosing ranges. Phenobarbital 
appears to have particular utility in those infants with poly-drug exposure in utero, perhaps due to 
a more global CNS depressive effect. Phenobarbital causes increased breakdown of many drugs 
metabolized by the cytochrome P450 system. Despite widespread use in newborns (80% of all 
neonatal seizures, up to 30,000 infants receive this drug each year) the safety profile has not been 
fully established.51 Phenobarbital has been reported to be associated with cognitive deficits in 
children taking it for complicated febrile seizures and animal data is suggestive of disruptions to 
synaptic development.52 However, there is no evidence of neurodevelopmental effects at 36 
months after antenatal exposure and no data on long term outcomes of infants treated for NAS.53 
At the current time, short term efficacy and safety of phenobarbital has been established and it 
remains a viable option for treating NAS.  
Clonidine 
Clonidine is a centrally acting α agonist used for hypertension and adult withdrawal 
syndromes by way of reducing global sympathetic tone. Mechanistically, this counters the 
symptoms of NAS driven by the hyperadrenergic state induced by withdrawal. While clonidine is 
less efficacious in the management of withdrawal symptoms in adults, it has an advantage as a 
non-opioid adjunctive treatment.54 Safety concerns include hypotension during treatment and 
rebound hypertension or arrhythmia following cessation. Though non-clinically significant 
hemodynamic changes are seen with use in NAS, the safety profile for inpatient use has been 
favorable.55 Clonidine has been systematically investigated mostly as an adjunct or rescue 
medication, but has also been studied as a replacement for morphine in a small pilot trial (Table 
2).  The relative efficacy compared to phenobarbital has not been established, though one clinical 
trial suggested longer duration of therapy with clonidine.47 
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Outpatient Treatment 
Pharmacologic treatment for the great majority of infants occurs in an inpatient hospital 
setting. However, a combined inpatient/outpatient treatment approach can reduce the total length 
of stay by ~50% compared to inpatient only, but is associated with significantly longer lengths of 
treatment.28,42,56 Methadone is the most commonly employed agent due to a longer half-life, though 
phenobarbital and morphine have been used. It should be noted that these findings are all based 
upon retrospective reviews and not randomized, prospective investigations.  It is likely that the 
ability to even be considered for outpatient treatment significantly impacted the length of stay in 
these studies. Additionally, there needs to be a comprehensive screening of the home environment 
to assess the suitability for outpatient treatment, as well as a robust infrastructure to track and 
manage outpatient treatment. Lastly, while shortened length of hospitalization is associated with 
less resource utilization, it is not clear that a shortened length of stay is beneficial for all infants. 
There may be individual mothers and infants for whom the inpatient stay allows for stabilization 
of medical, social, environmental, and/or psychiatric issues.  A more vigorous expansion to the 
outpatient setting must be made with caution, especially given the significant variability of 
methadone pharmacokinetics in infants with NAS. Although reports of small numbers of infants 
suggest the practice is safe, sudden infant death attributed to bed sharing and unsafe sleep practice 
has been recently reported in a cohort of infants weaned at home using morphine.56 
Long-term follow-up 
Adverse neurodevelopmental outcomes have been described in infants and children 
exposed to opioids in utero.  However, even though infants have been treated for NAS for over 30 
years, there is relatively little data on long-term neurodevelopmental outcomes. This is primarily 
due to small studies that are unable to differentiate the effects of in utero exposures and postnatal 
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treatments with confounding environmental influences. In general, opioid exposed children are 
more likely to have attention deficit disorders, disruptive behavior, and the need for comprehensive 
psychiatric referrals.57,58 Polydrug exposed children have smaller brains, thinner cortices, reduced 
cognitive ability and more behavioral problems.59 Studies of long term outcomes based upon short 
term exposure to drugs to treat NAS are extremely difficult to conduct. It is unlikely that the type 
of opioid used would have any impact on long term cognitive effects.  An unmet need in long term 
follow-up is an examination of the role of phenobarbital. 
Predictive factors  
Factors that influence the onset and severity of NAS remain incompletely understood. 
Outcomes typically evaluated include treatment for NAS, peak NAS score, total dose required for 
treatment, duration of treatment, and length of hospitalization. 
Maternal opiate dose: 
Many studies have attempted to define the correlation between maternal dose of methadone 
and NAS severity.26,60-62 A systematic review and meta-analysis suggest that maternal methadone 
or buprenorphine dose does not appear to correlate with the severity of NAS, a finding confirmed 
in the prospective, randomized Maternal Opioid Treatment: Human Experimental Research 
(MOTHER) trial.16,63 Low doses of methadone often lead to relapse or drug substitution to control 
symptoms. Higher methadone doses are associated with higher birth weight and head 
circumference. The prevailing approach in maternal management is to use the dose of methadone 
that best prevents maternal withdrawal. Optimizing maternal management will lead to better 
neonatal outcomes. These data in aggregate suggest that the appropriate maternal methadone dose 
will optimally ensure adherence and that dosing designed primarily to impact neonatal outcome 
will not be effective. 
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Maternal maintenance agent: 
Although methadone remains the most studied treatment for opiate dependence in 
pregnancy, initial studies have suggested that neonates exposed to buprenorphine in utero may be 
less likely to develop NAS compared to methadone.64 The MOTHER trial examined neonatal 
outcomes in pregnancies with exposure to buprenorphine versus methadone.16  Buprenorphine was 
associated with a significantly lower cumulative amount of morphine needed to treat NAS, shorter 
duration of treatment, and a 58% reduction in length of hospital stay. There were no differences 
between the buprenorphine and methadone groups with respect for the need for treatment, peak 
NAS score, or rate of serious maternal or neonatal adverse events. While the study suggested a 
less severe NAS course in neonates previously exposed to buprenorphine, a significantly higher 
dropout rate was observed in the buprenorphine group compared to the methadone group (33% vs 
18%). In addition, entry criteria excluded mothers who were also receiving benzodiazepines which 
are known to influence NAS. 
A recent Cochrane review indicated that existing data were inadequate to conclude whether 
methadone, buprenorphine, or other agents were superior for any relevant maternal or neonatal 
outcome.65 Relatively little information is available regarding the combined formulation of 
buprenorphine and naloxone compared to buprenorphine or methadone alone with respect to 
important NAS outcomes. However, some studies suggest less need for treatment, lower peak NAS 
scores, and shorter length of hospitalization in neonates exposed to the combined formulation.66, 
67   
Exposure to additional substances: 
Several studies have examined the combined effects of exposure to opiates and other 
substances on the incidence and severity of NAS. In a secondary analysis of the MOTHER study, 
14 
 
Kaltenbach and colleagues found that greater nicotine use at delivery (defined by number of 
cigarettes smoked in the twenty-four hours prior to birth) was associated with higher rates of 
treatment for NAS as well as the total dose of medication required.61 However, maternal nicotine 
use did not correlate with higher peak NAS scores or duration of treatment. The same study also 
examined the relationship between SSRIs and the development of NAS. Although there was no 
correlation between maternal SSRI use and whether an infant received treatment for NAS, in 
infants who did require treatment, maternal SSRI use was associated with higher peak NAS scores 
and total dose of opioid replacement medication. This contrasted with the work of Seligman and 
colleagues who did not find an association between use of antidepressants and the incidence or 
severity of NAS.68 However, this study did find an association between concomitant exposure to 
benzodiazepines and longer length of treatment, which confirmed earlier work on the topic.28,69  
Gestational age: 
Preterm neonates have a lower rate of NAS than term infants.68,70 This may be related to 
immaturity of the fetal brain and associated number of opiate receptors, lower cumulative drug 
exposure, less placental transfer, delayed hepatic and placental metabolism, and less drug 
deposition secondary to lower fat content. It is particularly important to note that assessment of 
NAS in preterm neonates is complicated by the lack of a validated scoring system specifically 
designed for this population who may have completely different autonomic responses. 
Pharmacogenomics: 
Genetic factors are known to contribute to opiate addiction in adults.71 Specifically, single-
nucleotide polymorphisms (SNPs) in the mu-opioid receptor (OPRM1), multidrug resistance 
(ABCB1), and catechol-O-methyltransferase (COMT) genes have been associated with adult 
opioid dependence.72-74 Initial studies in neonates with in utero opiate exposure demonstrated that 
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SNPs in OPRM1 and COMT genes were associated with improved outcomes in infants with 
NAS.75 Infants with the OPRRM1 118A>G AG/GG genotype had shortened length of stay [β = -
8.5 days (CI -14.9, -2.1), p=0.009] and were less likely to receive any treatment than AA infants 
[48 vs 72%; adjusted OR 0.76 (CI 0.63, 0.96), p=0.006].  The COMT 158A>G AG/GG genotype 
was associated with shortened length of stay [β = -10.8 days (CI -18.2, -3.4), p=0.005] and less 
treatment with >2 medications [18 vs 56%; adjusted OR 0.68 (CI 0.55, 0.85), p=0.001] than the 
AA genotype.  SNPs in the maternal OPRM1 were also associated with improved outcome in the 
newborns. Associations with the ABCB1 SNPs were not significant.  Microarray studies have 
demonstrated that SNPs in two additional opioid receptor genes in infants was associated with 
worse NAS outcomes.76 The presence of the PNOC rs732636 A allele (OR=3.8, p=0.004) was 
associated with the need for treatment with two medications and a longer hospital stay (5.8 days; 
p=0.01). The OPRK1 rs702764 C allele (OR=4.1, p=0.003) was also associated with the need for 
treatment with two medications. The OPRM1 rs1799971 G allele (β= -6.9 days, p=0.02) and 
COMT rs740603 A allele (β= -5.3 days, p=0.01) were associated with shorter length of stays. The 
OPRD1 rs204076 A allele in the mothers was associated with a longer length of stay by 6.6 days 
(p=0.008).  
Epigenetic changes (methylation of DNA which does not change the sequence, but does 
alter the function of the protein) have also been studied in NAS.77 Hypermethylation of the OPRM1 
promoter was seen at the -10 CpG in treated versus untreated infants [adjusted difference δ=3.2% 
(95% CI 0.3-6.0%), p=0.03; NS after multiple testing correction]. There was hypermethylation at 
the -14 [δ=4.9% (95% CI 1.8-8.1%), p=0.003], -10 [δ=5.0% (95% CI 2.3-7.7%), p=0.0005)], and 
+84 [δ=3.5% (95% CI 0.6 – 6.4), p=0.02] CpG sites in infants requiring treatment with two 
medications which remained significant for -14 and -10 after correction for multiple testing. While 
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ongoing work in the field is needed to confirm these initial findings, these data do suggest that 
genetic and epigenetic changes are playing an important role in incidence and severity of NAS. 
Pharmacogenetic characterization of mothers and infants may eventually help to optimize duration 
of monitoring for NAS and to customize drug and dose to each individual infant. Additionally, it 
may allow for individualized prenatal management of mothers with opioid dependence to optimize 
neonatal outcomes. 
Future Directions 
 The proliferation of electronic medical records and will lead to point-of-care clinical trials 
in which there is an initial randomization to a specific intervention or drug, followed by standard 
of care treatment outside of a rigid trial framework. In this way both inpatient and outpatient 
endpoints of interest can be collected in an efficient fashion. An example of this approach has been 
proposed to investigate the differential efficacy of buprenorphine compared to methadone78. 
Additionally, a number of large clinical trials investigating the use of commonly used agents are 
currently underway (NCT01958476, NCT01958476). Novel agents such ondansetron have been 
proposed prevent NAS, with a clinical trial examining ondansetron administered to pregnant 
women and their infants (up to age 5 days) currently enrolling (NCT01965704).79   
 Determination of current drug doses and regimens for the pharmacologic treatment of NAS 
has been empiric and extrapolated from other patient populations or limited to patient level data 
from infants with NAS. Pharmacokinetic modeling and simulation are techniques that allow a 
quantitative assessment that couples pharmacokinetic data with other covariates such as weight 
and age (gestational and postnatal). In addition, disease severity and pharmacogenetic factors 
which impact drug response or disposition can also be included in such models. The power of the 
models resides not only in the ability to characterize drug behavior with greater precision, but to 
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predict and simulate optimal drug doses. This is a common and widespread technique used in other 
conditions, but has been increasingly applied to NAS.45,80 Such methods have the potential to 
increase the efficiency of clinical trials in neonatology by establishing drug doses and regimens 
that account for known sources of variability (likely closer to the optimal dose at the start of the 
trial). Thus, modeling and simulation can change a clinical trial from exploratory to 
confirmatory.81    
Summary 
As the number of infants with in utero opioid exposure continues to rise, work is urgently 
needed to address significant knowledge gaps regarding optimal prenatal and postnatal care. 
Specific areas of focus should include:  
1) Reducing opioid exposure in women of child bearing age 
2) Institutional-wide and multidisciplinary approaches to standardize and continuously 
assess/improve NAS care protocols 
3) Use of big-data, outcomes methods and pragmatic clinical trials, as well as traditional 
randomized clinical trials to optimize treatment modalities in NAS 
4) Expanding maternal treatment programs to reduce the incidence and severity of NAS 
5) Better identifying and treating high-risk neonates through personalized genomic medicine 
6) Use of modeling and simulation to optimize drug therapy 
7) Increasing knowledge regarding the long-term effects of in utero opiate exposure and 
various neonatal treatment modalities 
Clearly a multidisciplinary approach is needed with Obstetricians, Pediatricians, Nurses, 
Social Workers, Addiction Specialists, and Politicians all working together if we hope to 
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significantly impact this important public health problem that is affecting this vulnerable 
population.  
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Table 1. Representative Morphine Treatment Regimens (based on Finnegan Scoring every 4 h) 
Weight based Symptom based16,19 (Doses are NOT weight based) 
 Initial dose: For two consecutive scores >8 
or one score ≥12, rescore in 1 h to verify. If 
still elevated:0.3-0.4 mg/kg/day divided 
every 4 h 
 Dose Increase:   
 20% per day for scores >24 total on three 
consecutive measurements or a single score 
≥ 12 (primarily related to NAS)   
Weaning Dose:  
 After 48 h of clinical stability, reduce dose 
by 10% of the total initial dose (based on 
starting weight) every 24h  
 Reduce dose when the sum of the previous 
three scores is < 18 and scores are not 
generally > 8    
 Cease therapy when dose is 0.15 
mg/kg/day 
 If inadequate control of symptoms when 
weaning, administer additional morphine.  
Then can increase the maintenance dose or 
keep it the same  
Adjunctive treatment:  
At dose of morphine 1.0 mg/kg/day initiate second 
medication * 
Initial dose: For two consecutive scores >8 or one 
score ≥12, rescore in 1 h to verify. If still elevated: 
Single NAS score Dose q4h 
9-12 0.04 mg 
13-16 0.08 mg 
17-20 0.12 mg 
21-24 0.16 mg 
>25 0.20 mg 
 
Dose Increase:   
Single NAS score Increase  Dose 
0-8 None 
9-12 0.02 mg 
13-16 0.04 mg 
17-20 0.06 mg 
 
Weaning Dose:  
 After 48 h of clinical stability, reduce dose 
by 0.02 mg every 24 h if scores are generally 
<8 
 Cease therapy when dose is 0.02 mg 
 
Adjunctive treatment:  
When morphine 1.6 mg/day initiate second  
medication* 
*phenobarbital loading dose of 20 mg/kg followed by 5 mg/kg/day OR clonidine 
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Table 2. Randomized Controlled Trials employing Clonidine 
Year Treatments n Clonidine dose 
(mcg/kg) 
Outcome in Length of Stay (LOS) 
or Length of Treatment (LOT) 
Agthe, 2009 
(Agthe, Kim 
et al. 2009) 
Morphine + clonidine 
 vs 
Morphine + placebo 
40 1.0 Q4 hours  
LOT 11 day (morphine and 
clonidine)  
 vs. 
 15 day (morphine alone) 
Suran 
(Surran, 
Visintainer 
et al. 2013) 
Morphine + clonidine 
 vs  
morphine + phenobarbital 
68 1-2 Q6 hours 
LOT 18.2 days (Morphine + 
phenobarbital)  
 vs  
13.6 days (Morphine + clonidine)  
Bada 2015 
(Bada, 
Sithisarn et 
al. 2015) 
Clonidine 
 vs 
Morphine  
31 0.625 Q3 hours 
LOT 39 days (morphine)  
 vs  
28 days (clonidine) 
  
31 
 
Figure 1:  Representative initiation doses for weight based compared to symptom based morphine dosing using the Finnegan score. In weight 
based regimens, a single initiation dose is used with the variable input patient weight. In symptom based regimens, a fixed (non-weight 
adjusted) regimen is used with the variable input severity of the NAS score.  An initiation score of >8 should be verified by repeat assessment 
before therapy is started. 
 
 
